hmmmm453的个人主页 - 老虎社区

hmmmm453

hmmmm453

暂无个人介绍

IP属地：海外

1关注

0粉丝

0主题

0勋章

2021-04-15

Interesting

Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?

2021-04-15

Hmm

Wall Street Breakfast: Retail Rebound

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577614128508291","uuid":"3577614128508291","gmtCreate":1614693720962,"gmtModify":1618496599551,"name":"hmmmm453","pinyin":"hmmmm453","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/838044a30f04cbddeb5c3169ebb255e7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":347634288,"gmtCreate":1618492304144,"gmtModify":1634292584722,"author":{"id":"3577614128508291","authorId":"3577614128508291","name":"hmmmm453","avatar":"https://static.tigerbbs.com/838044a30f04cbddeb5c3169ebb255e7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577614128508291","idStr":"3577614128508291"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/347634288","repostId":"2127001678","repostType":4,"repost":{"id":"2127001678","kind":"highlight","pubTimestamp":1618485180,"share":"https://www.laohu8.com/m/news/2127001678?lang=&edition=full","pubTime":"2021-04-15 19:13","market":"us","language":"en","title":"Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001678","media":"Motley Fool","summary":"There's no need for alarm just yet.","content":"<p><b>Pfizer</b> (NYSE:PFE) and <b>Moderna</b> (NASDAQ:MRNA) stand to make billions of dollars from their respective COVID-19 vaccines this year. The drugmakers hope to generate substantial recurring revenue going forward as well. However, a new COVID-19 vaccine is in development that could be a lot less expensive than either of these messenger RNA (mRNA) vaccines.</p>\n<p>In this <i>Motley Fool Live</i> video <b>recorded on April 7, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether this cheap vaccine candidate might even spell doom for Pfizer and Moderna.</p>\n<p><b>Keith Speights:</b><i> The New York Times</i> reported on Monday that there's an experimental COVID vaccine called NVD-HXP-S. This vaccine is entering early stage clinical studies in Brazil, Mexico, Thailand, and Vietnam. This vaccine uses the good old fashion approach of using chicken eggs to grow the key ingredient for the vaccine. It could be a lot cheaper than any of the COVID-19 vaccines that are currently on the market.</p>\n<p>Brian, do you think that this vaccine could be bad news for companies like Pfizer, and Moderna, which stand to make close to $20 billion or more this year from their COVID-19 vaccines?</p>\n<p><b>Brian Orelli:</b> Yeah. Given the large number of vaccines expected to be available, basically anything extra is bad news, and if it's at a lower cost or cheaper, that's even worse.</p>\n<p>This is really interesting technology. We grow vaccines in chicken eggs and typically for something like influenza, the flu, we've used the native virus. But this technology is actually using avian virus that expresses the coronavirus protein.</p>\n<p>The advantage there is that because it's the avian virus it now grows the heck of a lot better in eggs than that human flu virus would, and so you can get a heck of a lot more doses per egg. We'll have to see whether this acts as the antibodies in humans. The preclinical work in animal model seems pretty good, but there's always a chance that transitioning from animals to humans might not produce the same results.</p>\n<p>The other issue I think here is timing. They're going to finish the phase 1 in July, and so what's the infection rate going to look like at that point once most people in the US are vaccinated.</p>\n<p>You noted that they're doing the clinical trials in Brazil, and Mexico, Thailand, and Vietnam, so maybe they're trying to go after the areas where they're most likely to have infections. But then is the FDA going to allow clinical trials run there to get drugs approved in the US, and if not, then can you get enough people infected in the US once most people already have the vaccine?</p>\n<p><b>Speights:</b> It obviously remains to be seen what kind of efficacy this vaccine could deliver. I think to compete in developed nations like the US, and in Europe, it's going to have to achieve a pretty high efficacy, don't you think, to displace vaccines from Pfizer and Moderna?</p>\n<p><b>Orelli:</b> Yeah. Anything in the 60-70 percent range probably would be difficult when Pfizer and Moderna are up at 95.</p>\n<p><b>Speights:</b> Like you said, Brian, the phase 1 study is expected to wrap up in July. This isn't something that's going to impact Pfizer, or Moderna, or any of the other major vaccine players for that matter, this year. This is at best a 2022 type of factor, right?</p>\n<p><b>Orelli:</b> Yeah. Then as we've talked about many times, it's basically, do we need extra boosters for the variants? The other thing here is, I'm not sure how quickly they can transition this virus into the variants. I think it seems like it might be fairly simple steps to make a variant version of the vaccine, but I'm not 100 percent sure there.</p>\n<p><b>Speights:</b> I do think the story underscores the uncertainty related to the long-term COVID-19 vaccine market. There are just so many questions there, and I think that's why some of the stocks of companies that are making the vaccines haven't moved up even higher, is because of these uncertainties.</p>\n<p><b>Orelli:</b> I think Moderna is down substantially from its all-time highest, and I think that's probably <a href=\"https://laohu8.com/S/AONE\">one</a> of their reasons is due to the uncertainty of how much they're going to be able to sell, not this year, but next year and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/could-this-cheap-covid-19-vaccine-spell-doom-for-p/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) stand to make billions of dollars from their respective COVID-19 vaccines this year. The drugmakers hope to generate substantial recurring revenue going ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/could-this-cheap-covid-19-vaccine-spell-doom-for-p/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/04/15/could-this-cheap-covid-19-vaccine-spell-doom-for-p/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001678","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) stand to make billions of dollars from their respective COVID-19 vaccines this year. The drugmakers hope to generate substantial recurring revenue going forward as well. However, a new COVID-19 vaccine is in development that could be a lot less expensive than either of these messenger RNA (mRNA) vaccines.\nIn this Motley Fool Live video recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether this cheap vaccine candidate might even spell doom for Pfizer and Moderna.\nKeith Speights: The New York Times reported on Monday that there's an experimental COVID vaccine called NVD-HXP-S. This vaccine is entering early stage clinical studies in Brazil, Mexico, Thailand, and Vietnam. This vaccine uses the good old fashion approach of using chicken eggs to grow the key ingredient for the vaccine. It could be a lot cheaper than any of the COVID-19 vaccines that are currently on the market.\nBrian, do you think that this vaccine could be bad news for companies like Pfizer, and Moderna, which stand to make close to $20 billion or more this year from their COVID-19 vaccines?\nBrian Orelli: Yeah. Given the large number of vaccines expected to be available, basically anything extra is bad news, and if it's at a lower cost or cheaper, that's even worse.\nThis is really interesting technology. We grow vaccines in chicken eggs and typically for something like influenza, the flu, we've used the native virus. But this technology is actually using avian virus that expresses the coronavirus protein.\nThe advantage there is that because it's the avian virus it now grows the heck of a lot better in eggs than that human flu virus would, and so you can get a heck of a lot more doses per egg. We'll have to see whether this acts as the antibodies in humans. The preclinical work in animal model seems pretty good, but there's always a chance that transitioning from animals to humans might not produce the same results.\nThe other issue I think here is timing. They're going to finish the phase 1 in July, and so what's the infection rate going to look like at that point once most people in the US are vaccinated.\nYou noted that they're doing the clinical trials in Brazil, and Mexico, Thailand, and Vietnam, so maybe they're trying to go after the areas where they're most likely to have infections. But then is the FDA going to allow clinical trials run there to get drugs approved in the US, and if not, then can you get enough people infected in the US once most people already have the vaccine?\nSpeights: It obviously remains to be seen what kind of efficacy this vaccine could deliver. I think to compete in developed nations like the US, and in Europe, it's going to have to achieve a pretty high efficacy, don't you think, to displace vaccines from Pfizer and Moderna?\nOrelli: Yeah. Anything in the 60-70 percent range probably would be difficult when Pfizer and Moderna are up at 95.\nSpeights: Like you said, Brian, the phase 1 study is expected to wrap up in July. This isn't something that's going to impact Pfizer, or Moderna, or any of the other major vaccine players for that matter, this year. This is at best a 2022 type of factor, right?\nOrelli: Yeah. Then as we've talked about many times, it's basically, do we need extra boosters for the variants? The other thing here is, I'm not sure how quickly they can transition this virus into the variants. I think it seems like it might be fairly simple steps to make a variant version of the vaccine, but I'm not 100 percent sure there.\nSpeights: I do think the story underscores the uncertainty related to the long-term COVID-19 vaccine market. There are just so many questions there, and I think that's why some of the stocks of companies that are making the vaccines haven't moved up even higher, is because of these uncertainties.\nOrelli: I think Moderna is down substantially from its all-time highest, and I think that's probably one of their reasons is due to the uncertainty of how much they're going to be able to sell, not this year, but next year and beyond.","news_type":1},"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347635717,"gmtCreate":1618492222339,"gmtModify":1634292585182,"author":{"id":"3577614128508291","authorId":"3577614128508291","name":"hmmmm453","avatar":"https://static.tigerbbs.com/838044a30f04cbddeb5c3169ebb255e7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577614128508291","idStr":"3577614128508291"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347635717","repostId":"1128319234","repostType":4,"repost":{"id":"1128319234","kind":"news","pubTimestamp":1618486201,"share":"https://www.laohu8.com/m/news/1128319234?lang=&edition=full","pubTime":"2021-04-15 19:30","market":"us","language":"en","title":"Wall Street Breakfast: Retail Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1128319234","media":"seekingalpha","summary":"Retail reboundThe market will get some insight into how much the consumer is participating in the ec","content":"<p><b>Retail rebound</b></p><p>The market will get some insight into how much the consumer is participating in the economic recovery with the latest retail sales numbers today. S&amp;P futures(SPX), Nasdaq futures(NDX:IND)and Dow futures(INDU)are all in the green.</p><p>The Commerce Department will release March retail sales at 8:30 AM ET. Economists, on average, are looking for a strong rebound, with sales rising 5.9%, compared with a 3% drop in February. Core retail sales, which exclude autos, are forecast to rise 5%, reversing a 2.7% decline the month before. Retail sales have posted gains in just four months since the lockdown measures took hold last year, the most recent being a 5.3% gain for January.</p><p>If sales rise as anticipated, that would be a good indication that the latest round of $1,400 direct checks are making their way into the economy, providing the stimulus intended by the White House. A miss may indicate that the money is being channeled to other avenues, such as savings or asset purchases. The New York Fed said last week that 42 cents of every stimulus dollar were being saved, while 25% of funds are being spent and the rest is being used to pay down debt.</p><p>Reflation trade: For the stock market, a strong retail sales number could kick-start the reflation trade that favors cyclicals, which has lost steam of late. Despite a number of market-moving events, the S&amp;P(NYSEARCA:SPY)has struggled to gain traction in either direction and is down 0.1% for the week.</p><p>“The reflation trade has been taking a spring break,” says UBS Global Wealth Management CIO Mark Haefele. “We believe investors should continue to position for reflation” as vaccinations roll out and economies recover, he adds, according to Bloomberg. Financials(NYSEARCA:XLF), Industrials(NYSEARCA:XLI)and Energy(NYSEARCA:XLE)are likely to outperform.</p><p>Barclays strategist Emmanuel Cau says value is attractive as a hedge to overheating, but he's less positive on leisure, food retail and autos.</p><p>Economy accelerating, but still moderate: The Fed's Beige Book, out yesterday, said the U.S. economy is accelerating to a moderate pace, while some of the sectors hit hardest by the pandemic are showing signs of recovery.</p><p>\"Reports on tourism were more upbeat, bolstered by a pickup in demand for leisure activities and travel which contacts attributed to spring break, an easing of pandemic-related restrictions, increased vaccinations, and recent stimulus payments among other factors,\" the report said.</p><p>Economic growth and consumer spending \"accelerated over the last 6 weeks and pent-up demand for leisure activity and travel are starting to materialize,\" DataTrek Research writes. \"Inflation has picked up and companies face both labor shortages and supply chain disruptions. In the end, we continue to agree with the Fed that near-term inflation is transitory rather than structural, so we don’t think Chair Powell will view these inflationary pressures as a major red flag.\"</p><p>\"Moreover, the latest Fed Beige Book reports continue to show employers’ challenge of pulling workers back into the labor force,\" DataTrek adds. \"That will take time as vaccines roll out and childcare becomes more accessible, factors that are out of Chair Powell’s control. That’s why he and the Fed continue to signal holding rates near zero through at least 2022 to let the economy run hot enough to achieve their dual mandate.\"</p><p><b>ARK Invest snaps up Coinbase</b></p><p>ARK Investment Management bought shares of newly-public Coinbase Global(NASDAQ:COIN)for three different funds, while selling some of its Tesla(NASDAQ:TSLA)holdings.</p><p>Cathie Wood bought 89,589 shares of Coinbase for the ARK Fintech Innovation ETF(NYSEARCA:ARKF). She bought 512,535 shares of the crypto trading platform for the flagship ARK Innovation ETF(NYSEARCA:ARKK). And she added 147,081 COIN shares to the ARK Next Generation Internet ETF(NYSEARCA:ARKW). That was about $246M worth of Coinbase shares.</p><p>\"There are going to be great opportunities from now and five years to buy (Coinbase) on dips,\" Wood told Bloomberg. ARK thinks institutional interest could add $500K to the price of Bitcoin (BTC-USD). ARK sold 185,712 shares of Tesla from ARKK and 57,043 shares of the automaker from ARKW. Tesla is the top holding in ARKW and ARKK. Coinbase rose 30% in its debut yesterday, but closed down from where it opened the day.</p><p><b>SpaceX valued at $74B</b></p><p>SpaceX (SPACE) increased the size of its last equity raise, according to an SEC filing. The company brought in another $314M to add to the $850M previously reported. The new total equity raise of $1.16B values SpaceX at around $74B.</p><p>Investors in SpaceX are likely to be looking for a payoff from the Starlink (STRLK) Internet satellite business. There is speculation that Starlink will be set free in an IPO at some point. Looking at SpaceX's launch plans, a trip to the moon is planned for as early as 2022 with the Falcon 9 rocket slated to deliver an exploration rover on behalf of the United Arab Emirates.</p><p><b>Self-driving truck startup TuSimple is said to have raised $1.35B in IPO.</b></p><p>Self-driving truck startup TuSimple (TSP) is said to have raised $1.35B in an IPO, pricing the shares at $40, above an earlier range. TuSimple and a selling shareholder sold 34M shares at $40 each, above an estimated price of $35-$39, according to a Bloomberg report.</p><p>The company is backed by strategic investors, including Volkswagen AG’s(OTCPK:VLKAF)heavy-truck business The Traton Group, Navistar(NYSE:NAV), Goodyear(NASDAQ:GT), U.S. Xpress(NYSE:USX), NVIDIA(NASDAQ:NVDA)and United Parcel Service(NYSE:UPS).</p><p><b>Lucid Motors says its new electric vehicle is ready for the cold stuff</b></p><p>Lucid Motors (LUCIDM) updates on a cold weather test run on the Lucid Air at -40 degrees Celsius.</p><p>\"Lucid Air hit all its cold weather testing targets from quickly warming up, to starting, charging, and more. And despite cold temperatures, the quietness of the cabin was notable. Typically, interior components of a vehicle get noisier as its temperature drops. Not Lucid Air. Its NVH aspect - or Noise, Vibration, and Harshness rating - tested exceptionally well. And for luxury vehicle owners, that's a crucial outcome.\"</p><p><b>What else is happening...</b></p><p>Taiwan Semiconductor(NYSE:TSM)EPS beats by $0.04, beats on revenue.Shopify(NYSE:SHOP)loses some key execsamid growth push.Bitcoin (BTC-USD)hangs near record high.Oil(CL1:COM)hits highest since mid-Marchon strong demand outlook.Copper(HG1:COM)on path to $15K/ton in 2025thanks to green transition, Goldman says.AstraZenca’s(NASDAQ:AZN)COVID-19 vaccine trumps Ocugen's Covaxinin Indian study.</p><p><b>Today's Markets</b></p><p><b>In Asia,</b>Japan+0.1%. Hong Kong-0.4%. China-0.5%. India+0.6%.</p><p><b>In Europe,</b>at midday, London+0.4%. Paris+0.3%. Frankfurt+0.3%.</p><p><b>Futures at 6:20,</b>Dow+0.4%. S&amp;P+0.4%. Nasdaq+0.5%. Crude-0.7%to $62.70. Gold+0.6%at $1747.60. Bitcoin-2%to $62311.</p><p><b>Ten-year Treasury Yield</b>-2 bps to1.615%</p><p><b>Today's Economic Calendar</b></p><p>8:30&nbsp;Initial Jobless Claims</p><p>8:30&nbsp;Philly Fed Business Outlook</p><p>8:30&nbsp;Retail Sales</p><p>8:30&nbsp;Empire State Mfg Survey</p><p>9:15&nbsp;Industrial Production</p><p>10:00&nbsp;Business Inventories</p><p>10:00&nbsp;NAHB Housing Market Index</p><p>10:30&nbsp;EIA Natural Gas Inventory</p><p>11:30&nbsp;Fed's Bostic: \"The Atlantic's Progress Report: The State of the Black Community\"</p><p>2:00 PMFed’s Daly Speech</p><p>4:00 PMFed’s Mester: \"Economic Inclusion\"</p><p>4:00 PMTreasury International Capital</p><p>4:30 PMFed Balance Sheet</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Breakfast: Retail Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Breakfast: Retail Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4419172-wall-street-breakfast-retail-rebound><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Retail reboundThe market will get some insight into how much the consumer is participating in the economic recovery with the latest retail sales numbers today. S&P futures(SPX), Nasdaq futures(NDX:IND...</p>\n\n<a href=\"https://seekingalpha.com/article/4419172-wall-street-breakfast-retail-rebound\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4419172-wall-street-breakfast-retail-rebound","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128319234","content_text":"Retail reboundThe market will get some insight into how much the consumer is participating in the economic recovery with the latest retail sales numbers today. S&P futures(SPX), Nasdaq futures(NDX:IND)and Dow futures(INDU)are all in the green.The Commerce Department will release March retail sales at 8:30 AM ET. Economists, on average, are looking for a strong rebound, with sales rising 5.9%, compared with a 3% drop in February. Core retail sales, which exclude autos, are forecast to rise 5%, reversing a 2.7% decline the month before. Retail sales have posted gains in just four months since the lockdown measures took hold last year, the most recent being a 5.3% gain for January.If sales rise as anticipated, that would be a good indication that the latest round of $1,400 direct checks are making their way into the economy, providing the stimulus intended by the White House. A miss may indicate that the money is being channeled to other avenues, such as savings or asset purchases. The New York Fed said last week that 42 cents of every stimulus dollar were being saved, while 25% of funds are being spent and the rest is being used to pay down debt.Reflation trade: For the stock market, a strong retail sales number could kick-start the reflation trade that favors cyclicals, which has lost steam of late. Despite a number of market-moving events, the S&P(NYSEARCA:SPY)has struggled to gain traction in either direction and is down 0.1% for the week.“The reflation trade has been taking a spring break,” says UBS Global Wealth Management CIO Mark Haefele. “We believe investors should continue to position for reflation” as vaccinations roll out and economies recover, he adds, according to Bloomberg. Financials(NYSEARCA:XLF), Industrials(NYSEARCA:XLI)and Energy(NYSEARCA:XLE)are likely to outperform.Barclays strategist Emmanuel Cau says value is attractive as a hedge to overheating, but he's less positive on leisure, food retail and autos.Economy accelerating, but still moderate: The Fed's Beige Book, out yesterday, said the U.S. economy is accelerating to a moderate pace, while some of the sectors hit hardest by the pandemic are showing signs of recovery.\"Reports on tourism were more upbeat, bolstered by a pickup in demand for leisure activities and travel which contacts attributed to spring break, an easing of pandemic-related restrictions, increased vaccinations, and recent stimulus payments among other factors,\" the report said.Economic growth and consumer spending \"accelerated over the last 6 weeks and pent-up demand for leisure activity and travel are starting to materialize,\" DataTrek Research writes. \"Inflation has picked up and companies face both labor shortages and supply chain disruptions. In the end, we continue to agree with the Fed that near-term inflation is transitory rather than structural, so we don’t think Chair Powell will view these inflationary pressures as a major red flag.\"\"Moreover, the latest Fed Beige Book reports continue to show employers’ challenge of pulling workers back into the labor force,\" DataTrek adds. \"That will take time as vaccines roll out and childcare becomes more accessible, factors that are out of Chair Powell’s control. That’s why he and the Fed continue to signal holding rates near zero through at least 2022 to let the economy run hot enough to achieve their dual mandate.\"ARK Invest snaps up CoinbaseARK Investment Management bought shares of newly-public Coinbase Global(NASDAQ:COIN)for three different funds, while selling some of its Tesla(NASDAQ:TSLA)holdings.Cathie Wood bought 89,589 shares of Coinbase for the ARK Fintech Innovation ETF(NYSEARCA:ARKF). She bought 512,535 shares of the crypto trading platform for the flagship ARK Innovation ETF(NYSEARCA:ARKK). And she added 147,081 COIN shares to the ARK Next Generation Internet ETF(NYSEARCA:ARKW). That was about $246M worth of Coinbase shares.\"There are going to be great opportunities from now and five years to buy (Coinbase) on dips,\" Wood told Bloomberg. ARK thinks institutional interest could add $500K to the price of Bitcoin (BTC-USD). ARK sold 185,712 shares of Tesla from ARKK and 57,043 shares of the automaker from ARKW. Tesla is the top holding in ARKW and ARKK. Coinbase rose 30% in its debut yesterday, but closed down from where it opened the day.SpaceX valued at $74BSpaceX (SPACE) increased the size of its last equity raise, according to an SEC filing. The company brought in another $314M to add to the $850M previously reported. The new total equity raise of $1.16B values SpaceX at around $74B.Investors in SpaceX are likely to be looking for a payoff from the Starlink (STRLK) Internet satellite business. There is speculation that Starlink will be set free in an IPO at some point. Looking at SpaceX's launch plans, a trip to the moon is planned for as early as 2022 with the Falcon 9 rocket slated to deliver an exploration rover on behalf of the United Arab Emirates.Self-driving truck startup TuSimple is said to have raised $1.35B in IPO.Self-driving truck startup TuSimple (TSP) is said to have raised $1.35B in an IPO, pricing the shares at $40, above an earlier range. TuSimple and a selling shareholder sold 34M shares at $40 each, above an estimated price of $35-$39, according to a Bloomberg report.The company is backed by strategic investors, including Volkswagen AG’s(OTCPK:VLKAF)heavy-truck business The Traton Group, Navistar(NYSE:NAV), Goodyear(NASDAQ:GT), U.S. Xpress(NYSE:USX), NVIDIA(NASDAQ:NVDA)and United Parcel Service(NYSE:UPS).Lucid Motors says its new electric vehicle is ready for the cold stuffLucid Motors (LUCIDM) updates on a cold weather test run on the Lucid Air at -40 degrees Celsius.\"Lucid Air hit all its cold weather testing targets from quickly warming up, to starting, charging, and more. And despite cold temperatures, the quietness of the cabin was notable. Typically, interior components of a vehicle get noisier as its temperature drops. Not Lucid Air. Its NVH aspect - or Noise, Vibration, and Harshness rating - tested exceptionally well. And for luxury vehicle owners, that's a crucial outcome.\"What else is happening...Taiwan Semiconductor(NYSE:TSM)EPS beats by $0.04, beats on revenue.Shopify(NYSE:SHOP)loses some key execsamid growth push.Bitcoin (BTC-USD)hangs near record high.Oil(CL1:COM)hits highest since mid-Marchon strong demand outlook.Copper(HG1:COM)on path to $15K/ton in 2025thanks to green transition, Goldman says.AstraZenca’s(NASDAQ:AZN)COVID-19 vaccine trumps Ocugen's Covaxinin Indian study.Today's MarketsIn Asia,Japan+0.1%. Hong Kong-0.4%. China-0.5%. India+0.6%.In Europe,at midday, London+0.4%. Paris+0.3%. Frankfurt+0.3%.Futures at 6:20,Dow+0.4%. S&P+0.4%. Nasdaq+0.5%. Crude-0.7%to $62.70. Gold+0.6%at $1747.60. Bitcoin-2%to $62311.Ten-year Treasury Yield-2 bps to1.615%Today's Economic Calendar8:30 Initial Jobless Claims8:30 Philly Fed Business Outlook8:30 Retail Sales8:30 Empire State Mfg Survey9:15 Industrial Production10:00 Business Inventories10:00 NAHB Housing Market Index10:30 EIA Natural Gas Inventory11:30 Fed's Bostic: \"The Atlantic's Progress Report: The State of the Black Community\"2:00 PMFed’s Daly Speech4:00 PMFed’s Mester: \"Economic Inclusion\"4:00 PMTreasury International Capital4:30 PMFed Balance Sheet","news_type":1},"isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":347634288,"gmtCreate":1618492304144,"gmtModify":1634292584722,"author":{"id":"3577614128508291","authorId":"3577614128508291","name":"hmmmm453","avatar":"https://static.tigerbbs.com/838044a30f04cbddeb5c3169ebb255e7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577614128508291","authorIdStr":"3577614128508291"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/347634288","repostId":"2127001678","repostType":4,"repost":{"id":"2127001678","kind":"highlight","pubTimestamp":1618485180,"share":"https://www.laohu8.com/m/news/2127001678?lang=&edition=full","pubTime":"2021-04-15 19:13","market":"us","language":"en","title":"Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127001678","media":"Motley Fool","summary":"There's no need for alarm just yet.","content":"<p><b>Pfizer</b> (NYSE:PFE) and <b>Moderna</b> (NASDAQ:MRNA) stand to make billions of dollars from their respective COVID-19 vaccines this year. The drugmakers hope to generate substantial recurring revenue going forward as well. However, a new COVID-19 vaccine is in development that could be a lot less expensive than either of these messenger RNA (mRNA) vaccines.</p>\n<p>In this <i>Motley Fool Live</i> video <b>recorded on April 7, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether this cheap vaccine candidate might even spell doom for Pfizer and Moderna.</p>\n<p><b>Keith Speights:</b><i> The New York Times</i> reported on Monday that there's an experimental COVID vaccine called NVD-HXP-S. This vaccine is entering early stage clinical studies in Brazil, Mexico, Thailand, and Vietnam. This vaccine uses the good old fashion approach of using chicken eggs to grow the key ingredient for the vaccine. It could be a lot cheaper than any of the COVID-19 vaccines that are currently on the market.</p>\n<p>Brian, do you think that this vaccine could be bad news for companies like Pfizer, and Moderna, which stand to make close to $20 billion or more this year from their COVID-19 vaccines?</p>\n<p><b>Brian Orelli:</b> Yeah. Given the large number of vaccines expected to be available, basically anything extra is bad news, and if it's at a lower cost or cheaper, that's even worse.</p>\n<p>This is really interesting technology. We grow vaccines in chicken eggs and typically for something like influenza, the flu, we've used the native virus. But this technology is actually using avian virus that expresses the coronavirus protein.</p>\n<p>The advantage there is that because it's the avian virus it now grows the heck of a lot better in eggs than that human flu virus would, and so you can get a heck of a lot more doses per egg. We'll have to see whether this acts as the antibodies in humans. The preclinical work in animal model seems pretty good, but there's always a chance that transitioning from animals to humans might not produce the same results.</p>\n<p>The other issue I think here is timing. They're going to finish the phase 1 in July, and so what's the infection rate going to look like at that point once most people in the US are vaccinated.</p>\n<p>You noted that they're doing the clinical trials in Brazil, and Mexico, Thailand, and Vietnam, so maybe they're trying to go after the areas where they're most likely to have infections. But then is the FDA going to allow clinical trials run there to get drugs approved in the US, and if not, then can you get enough people infected in the US once most people already have the vaccine?</p>\n<p><b>Speights:</b> It obviously remains to be seen what kind of efficacy this vaccine could deliver. I think to compete in developed nations like the US, and in Europe, it's going to have to achieve a pretty high efficacy, don't you think, to displace vaccines from Pfizer and Moderna?</p>\n<p><b>Orelli:</b> Yeah. Anything in the 60-70 percent range probably would be difficult when Pfizer and Moderna are up at 95.</p>\n<p><b>Speights:</b> Like you said, Brian, the phase 1 study is expected to wrap up in July. This isn't something that's going to impact Pfizer, or Moderna, or any of the other major vaccine players for that matter, this year. This is at best a 2022 type of factor, right?</p>\n<p><b>Orelli:</b> Yeah. Then as we've talked about many times, it's basically, do we need extra boosters for the variants? The other thing here is, I'm not sure how quickly they can transition this virus into the variants. I think it seems like it might be fairly simple steps to make a variant version of the vaccine, but I'm not 100 percent sure there.</p>\n<p><b>Speights:</b> I do think the story underscores the uncertainty related to the long-term COVID-19 vaccine market. There are just so many questions there, and I think that's why some of the stocks of companies that are making the vaccines haven't moved up even higher, is because of these uncertainties.</p>\n<p><b>Orelli:</b> I think Moderna is down substantially from its all-time highest, and I think that's probably <a href=\"https://laohu8.com/S/AONE\">one</a> of their reasons is due to the uncertainty of how much they're going to be able to sell, not this year, but next year and beyond.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/15/could-this-cheap-covid-19-vaccine-spell-doom-for-p/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) stand to make billions of dollars from their respective COVID-19 vaccines this year. The drugmakers hope to generate substantial recurring revenue going ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/15/could-this-cheap-covid-19-vaccine-spell-doom-for-p/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/04/15/could-this-cheap-covid-19-vaccine-spell-doom-for-p/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127001678","content_text":"Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) stand to make billions of dollars from their respective COVID-19 vaccines this year. The drugmakers hope to generate substantial recurring revenue going forward as well. However, a new COVID-19 vaccine is in development that could be a lot less expensive than either of these messenger RNA (mRNA) vaccines.\nIn this Motley Fool Live video recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether this cheap vaccine candidate might even spell doom for Pfizer and Moderna.\nKeith Speights: The New York Times reported on Monday that there's an experimental COVID vaccine called NVD-HXP-S. This vaccine is entering early stage clinical studies in Brazil, Mexico, Thailand, and Vietnam. This vaccine uses the good old fashion approach of using chicken eggs to grow the key ingredient for the vaccine. It could be a lot cheaper than any of the COVID-19 vaccines that are currently on the market.\nBrian, do you think that this vaccine could be bad news for companies like Pfizer, and Moderna, which stand to make close to $20 billion or more this year from their COVID-19 vaccines?\nBrian Orelli: Yeah. Given the large number of vaccines expected to be available, basically anything extra is bad news, and if it's at a lower cost or cheaper, that's even worse.\nThis is really interesting technology. We grow vaccines in chicken eggs and typically for something like influenza, the flu, we've used the native virus. But this technology is actually using avian virus that expresses the coronavirus protein.\nThe advantage there is that because it's the avian virus it now grows the heck of a lot better in eggs than that human flu virus would, and so you can get a heck of a lot more doses per egg. We'll have to see whether this acts as the antibodies in humans. The preclinical work in animal model seems pretty good, but there's always a chance that transitioning from animals to humans might not produce the same results.\nThe other issue I think here is timing. They're going to finish the phase 1 in July, and so what's the infection rate going to look like at that point once most people in the US are vaccinated.\nYou noted that they're doing the clinical trials in Brazil, and Mexico, Thailand, and Vietnam, so maybe they're trying to go after the areas where they're most likely to have infections. But then is the FDA going to allow clinical trials run there to get drugs approved in the US, and if not, then can you get enough people infected in the US once most people already have the vaccine?\nSpeights: It obviously remains to be seen what kind of efficacy this vaccine could deliver. I think to compete in developed nations like the US, and in Europe, it's going to have to achieve a pretty high efficacy, don't you think, to displace vaccines from Pfizer and Moderna?\nOrelli: Yeah. Anything in the 60-70 percent range probably would be difficult when Pfizer and Moderna are up at 95.\nSpeights: Like you said, Brian, the phase 1 study is expected to wrap up in July. This isn't something that's going to impact Pfizer, or Moderna, or any of the other major vaccine players for that matter, this year. This is at best a 2022 type of factor, right?\nOrelli: Yeah. Then as we've talked about many times, it's basically, do we need extra boosters for the variants? The other thing here is, I'm not sure how quickly they can transition this virus into the variants. I think it seems like it might be fairly simple steps to make a variant version of the vaccine, but I'm not 100 percent sure there.\nSpeights: I do think the story underscores the uncertainty related to the long-term COVID-19 vaccine market. There are just so many questions there, and I think that's why some of the stocks of companies that are making the vaccines haven't moved up even higher, is because of these uncertainties.\nOrelli: I think Moderna is down substantially from its all-time highest, and I think that's probably one of their reasons is due to the uncertainty of how much they're going to be able to sell, not this year, but next year and beyond.","news_type":1},"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347635717,"gmtCreate":1618492222339,"gmtModify":1634292585182,"author":{"id":"3577614128508291","authorId":"3577614128508291","name":"hmmmm453","avatar":"https://static.tigerbbs.com/838044a30f04cbddeb5c3169ebb255e7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577614128508291","authorIdStr":"3577614128508291"},"themes":[],"htmlText":"Hmm","listText":"Hmm","text":"Hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347635717","repostId":"1128319234","repostType":4,"repost":{"id":"1128319234","kind":"news","pubTimestamp":1618486201,"share":"https://www.laohu8.com/m/news/1128319234?lang=&edition=full","pubTime":"2021-04-15 19:30","market":"us","language":"en","title":"Wall Street Breakfast: Retail Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1128319234","media":"seekingalpha","summary":"Retail reboundThe market will get some insight into how much the consumer is participating in the ec","content":"<p><b>Retail rebound</b></p><p>The market will get some insight into how much the consumer is participating in the economic recovery with the latest retail sales numbers today. S&amp;P futures(SPX), Nasdaq futures(NDX:IND)and Dow futures(INDU)are all in the green.</p><p>The Commerce Department will release March retail sales at 8:30 AM ET. Economists, on average, are looking for a strong rebound, with sales rising 5.9%, compared with a 3% drop in February. Core retail sales, which exclude autos, are forecast to rise 5%, reversing a 2.7% decline the month before. Retail sales have posted gains in just four months since the lockdown measures took hold last year, the most recent being a 5.3% gain for January.</p><p>If sales rise as anticipated, that would be a good indication that the latest round of $1,400 direct checks are making their way into the economy, providing the stimulus intended by the White House. A miss may indicate that the money is being channeled to other avenues, such as savings or asset purchases. The New York Fed said last week that 42 cents of every stimulus dollar were being saved, while 25% of funds are being spent and the rest is being used to pay down debt.</p><p>Reflation trade: For the stock market, a strong retail sales number could kick-start the reflation trade that favors cyclicals, which has lost steam of late. Despite a number of market-moving events, the S&amp;P(NYSEARCA:SPY)has struggled to gain traction in either direction and is down 0.1% for the week.</p><p>“The reflation trade has been taking a spring break,” says UBS Global Wealth Management CIO Mark Haefele. “We believe investors should continue to position for reflation” as vaccinations roll out and economies recover, he adds, according to Bloomberg. Financials(NYSEARCA:XLF), Industrials(NYSEARCA:XLI)and Energy(NYSEARCA:XLE)are likely to outperform.</p><p>Barclays strategist Emmanuel Cau says value is attractive as a hedge to overheating, but he's less positive on leisure, food retail and autos.</p><p>Economy accelerating, but still moderate: The Fed's Beige Book, out yesterday, said the U.S. economy is accelerating to a moderate pace, while some of the sectors hit hardest by the pandemic are showing signs of recovery.</p><p>\"Reports on tourism were more upbeat, bolstered by a pickup in demand for leisure activities and travel which contacts attributed to spring break, an easing of pandemic-related restrictions, increased vaccinations, and recent stimulus payments among other factors,\" the report said.</p><p>Economic growth and consumer spending \"accelerated over the last 6 weeks and pent-up demand for leisure activity and travel are starting to materialize,\" DataTrek Research writes. \"Inflation has picked up and companies face both labor shortages and supply chain disruptions. In the end, we continue to agree with the Fed that near-term inflation is transitory rather than structural, so we don’t think Chair Powell will view these inflationary pressures as a major red flag.\"</p><p>\"Moreover, the latest Fed Beige Book reports continue to show employers’ challenge of pulling workers back into the labor force,\" DataTrek adds. \"That will take time as vaccines roll out and childcare becomes more accessible, factors that are out of Chair Powell’s control. That’s why he and the Fed continue to signal holding rates near zero through at least 2022 to let the economy run hot enough to achieve their dual mandate.\"</p><p><b>ARK Invest snaps up Coinbase</b></p><p>ARK Investment Management bought shares of newly-public Coinbase Global(NASDAQ:COIN)for three different funds, while selling some of its Tesla(NASDAQ:TSLA)holdings.</p><p>Cathie Wood bought 89,589 shares of Coinbase for the ARK Fintech Innovation ETF(NYSEARCA:ARKF). She bought 512,535 shares of the crypto trading platform for the flagship ARK Innovation ETF(NYSEARCA:ARKK). And she added 147,081 COIN shares to the ARK Next Generation Internet ETF(NYSEARCA:ARKW). That was about $246M worth of Coinbase shares.</p><p>\"There are going to be great opportunities from now and five years to buy (Coinbase) on dips,\" Wood told Bloomberg. ARK thinks institutional interest could add $500K to the price of Bitcoin (BTC-USD). ARK sold 185,712 shares of Tesla from ARKK and 57,043 shares of the automaker from ARKW. Tesla is the top holding in ARKW and ARKK. Coinbase rose 30% in its debut yesterday, but closed down from where it opened the day.</p><p><b>SpaceX valued at $74B</b></p><p>SpaceX (SPACE) increased the size of its last equity raise, according to an SEC filing. The company brought in another $314M to add to the $850M previously reported. The new total equity raise of $1.16B values SpaceX at around $74B.</p><p>Investors in SpaceX are likely to be looking for a payoff from the Starlink (STRLK) Internet satellite business. There is speculation that Starlink will be set free in an IPO at some point. Looking at SpaceX's launch plans, a trip to the moon is planned for as early as 2022 with the Falcon 9 rocket slated to deliver an exploration rover on behalf of the United Arab Emirates.</p><p><b>Self-driving truck startup TuSimple is said to have raised $1.35B in IPO.</b></p><p>Self-driving truck startup TuSimple (TSP) is said to have raised $1.35B in an IPO, pricing the shares at $40, above an earlier range. TuSimple and a selling shareholder sold 34M shares at $40 each, above an estimated price of $35-$39, according to a Bloomberg report.</p><p>The company is backed by strategic investors, including Volkswagen AG’s(OTCPK:VLKAF)heavy-truck business The Traton Group, Navistar(NYSE:NAV), Goodyear(NASDAQ:GT), U.S. Xpress(NYSE:USX), NVIDIA(NASDAQ:NVDA)and United Parcel Service(NYSE:UPS).</p><p><b>Lucid Motors says its new electric vehicle is ready for the cold stuff</b></p><p>Lucid Motors (LUCIDM) updates on a cold weather test run on the Lucid Air at -40 degrees Celsius.</p><p>\"Lucid Air hit all its cold weather testing targets from quickly warming up, to starting, charging, and more. And despite cold temperatures, the quietness of the cabin was notable. Typically, interior components of a vehicle get noisier as its temperature drops. Not Lucid Air. Its NVH aspect - or Noise, Vibration, and Harshness rating - tested exceptionally well. And for luxury vehicle owners, that's a crucial outcome.\"</p><p><b>What else is happening...</b></p><p>Taiwan Semiconductor(NYSE:TSM)EPS beats by $0.04, beats on revenue.Shopify(NYSE:SHOP)loses some key execsamid growth push.Bitcoin (BTC-USD)hangs near record high.Oil(CL1:COM)hits highest since mid-Marchon strong demand outlook.Copper(HG1:COM)on path to $15K/ton in 2025thanks to green transition, Goldman says.AstraZenca’s(NASDAQ:AZN)COVID-19 vaccine trumps Ocugen's Covaxinin Indian study.</p><p><b>Today's Markets</b></p><p><b>In Asia,</b>Japan+0.1%. Hong Kong-0.4%. China-0.5%. India+0.6%.</p><p><b>In Europe,</b>at midday, London+0.4%. Paris+0.3%. Frankfurt+0.3%.</p><p><b>Futures at 6:20,</b>Dow+0.4%. S&amp;P+0.4%. Nasdaq+0.5%. Crude-0.7%to $62.70. Gold+0.6%at $1747.60. Bitcoin-2%to $62311.</p><p><b>Ten-year Treasury Yield</b>-2 bps to1.615%</p><p><b>Today's Economic Calendar</b></p><p>8:30&nbsp;Initial Jobless Claims</p><p>8:30&nbsp;Philly Fed Business Outlook</p><p>8:30&nbsp;Retail Sales</p><p>8:30&nbsp;Empire State Mfg Survey</p><p>9:15&nbsp;Industrial Production</p><p>10:00&nbsp;Business Inventories</p><p>10:00&nbsp;NAHB Housing Market Index</p><p>10:30&nbsp;EIA Natural Gas Inventory</p><p>11:30&nbsp;Fed's Bostic: \"The Atlantic's Progress Report: The State of the Black Community\"</p><p>2:00 PMFed’s Daly Speech</p><p>4:00 PMFed’s Mester: \"Economic Inclusion\"</p><p>4:00 PMTreasury International Capital</p><p>4:30 PMFed Balance Sheet</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Breakfast: Retail Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Breakfast: Retail Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 19:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4419172-wall-street-breakfast-retail-rebound><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Retail reboundThe market will get some insight into how much the consumer is participating in the economic recovery with the latest retail sales numbers today. S&P futures(SPX), Nasdaq futures(NDX:IND...</p>\n\n<a href=\"https://seekingalpha.com/article/4419172-wall-street-breakfast-retail-rebound\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPY":"标普500ETF",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://seekingalpha.com/article/4419172-wall-street-breakfast-retail-rebound","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128319234","content_text":"Retail reboundThe market will get some insight into how much the consumer is participating in the economic recovery with the latest retail sales numbers today. S&P futures(SPX), Nasdaq futures(NDX:IND)and Dow futures(INDU)are all in the green.The Commerce Department will release March retail sales at 8:30 AM ET. Economists, on average, are looking for a strong rebound, with sales rising 5.9%, compared with a 3% drop in February. Core retail sales, which exclude autos, are forecast to rise 5%, reversing a 2.7% decline the month before. Retail sales have posted gains in just four months since the lockdown measures took hold last year, the most recent being a 5.3% gain for January.If sales rise as anticipated, that would be a good indication that the latest round of $1,400 direct checks are making their way into the economy, providing the stimulus intended by the White House. A miss may indicate that the money is being channeled to other avenues, such as savings or asset purchases. The New York Fed said last week that 42 cents of every stimulus dollar were being saved, while 25% of funds are being spent and the rest is being used to pay down debt.Reflation trade: For the stock market, a strong retail sales number could kick-start the reflation trade that favors cyclicals, which has lost steam of late. Despite a number of market-moving events, the S&P(NYSEARCA:SPY)has struggled to gain traction in either direction and is down 0.1% for the week.“The reflation trade has been taking a spring break,” says UBS Global Wealth Management CIO Mark Haefele. “We believe investors should continue to position for reflation” as vaccinations roll out and economies recover, he adds, according to Bloomberg. Financials(NYSEARCA:XLF), Industrials(NYSEARCA:XLI)and Energy(NYSEARCA:XLE)are likely to outperform.Barclays strategist Emmanuel Cau says value is attractive as a hedge to overheating, but he's less positive on leisure, food retail and autos.Economy accelerating, but still moderate: The Fed's Beige Book, out yesterday, said the U.S. economy is accelerating to a moderate pace, while some of the sectors hit hardest by the pandemic are showing signs of recovery.\"Reports on tourism were more upbeat, bolstered by a pickup in demand for leisure activities and travel which contacts attributed to spring break, an easing of pandemic-related restrictions, increased vaccinations, and recent stimulus payments among other factors,\" the report said.Economic growth and consumer spending \"accelerated over the last 6 weeks and pent-up demand for leisure activity and travel are starting to materialize,\" DataTrek Research writes. \"Inflation has picked up and companies face both labor shortages and supply chain disruptions. In the end, we continue to agree with the Fed that near-term inflation is transitory rather than structural, so we don’t think Chair Powell will view these inflationary pressures as a major red flag.\"\"Moreover, the latest Fed Beige Book reports continue to show employers’ challenge of pulling workers back into the labor force,\" DataTrek adds. \"That will take time as vaccines roll out and childcare becomes more accessible, factors that are out of Chair Powell’s control. That’s why he and the Fed continue to signal holding rates near zero through at least 2022 to let the economy run hot enough to achieve their dual mandate.\"ARK Invest snaps up CoinbaseARK Investment Management bought shares of newly-public Coinbase Global(NASDAQ:COIN)for three different funds, while selling some of its Tesla(NASDAQ:TSLA)holdings.Cathie Wood bought 89,589 shares of Coinbase for the ARK Fintech Innovation ETF(NYSEARCA:ARKF). She bought 512,535 shares of the crypto trading platform for the flagship ARK Innovation ETF(NYSEARCA:ARKK). And she added 147,081 COIN shares to the ARK Next Generation Internet ETF(NYSEARCA:ARKW). That was about $246M worth of Coinbase shares.\"There are going to be great opportunities from now and five years to buy (Coinbase) on dips,\" Wood told Bloomberg. ARK thinks institutional interest could add $500K to the price of Bitcoin (BTC-USD). ARK sold 185,712 shares of Tesla from ARKK and 57,043 shares of the automaker from ARKW. Tesla is the top holding in ARKW and ARKK. Coinbase rose 30% in its debut yesterday, but closed down from where it opened the day.SpaceX valued at $74BSpaceX (SPACE) increased the size of its last equity raise, according to an SEC filing. The company brought in another $314M to add to the $850M previously reported. The new total equity raise of $1.16B values SpaceX at around $74B.Investors in SpaceX are likely to be looking for a payoff from the Starlink (STRLK) Internet satellite business. There is speculation that Starlink will be set free in an IPO at some point. Looking at SpaceX's launch plans, a trip to the moon is planned for as early as 2022 with the Falcon 9 rocket slated to deliver an exploration rover on behalf of the United Arab Emirates.Self-driving truck startup TuSimple is said to have raised $1.35B in IPO.Self-driving truck startup TuSimple (TSP) is said to have raised $1.35B in an IPO, pricing the shares at $40, above an earlier range. TuSimple and a selling shareholder sold 34M shares at $40 each, above an estimated price of $35-$39, according to a Bloomberg report.The company is backed by strategic investors, including Volkswagen AG’s(OTCPK:VLKAF)heavy-truck business The Traton Group, Navistar(NYSE:NAV), Goodyear(NASDAQ:GT), U.S. Xpress(NYSE:USX), NVIDIA(NASDAQ:NVDA)and United Parcel Service(NYSE:UPS).Lucid Motors says its new electric vehicle is ready for the cold stuffLucid Motors (LUCIDM) updates on a cold weather test run on the Lucid Air at -40 degrees Celsius.\"Lucid Air hit all its cold weather testing targets from quickly warming up, to starting, charging, and more. And despite cold temperatures, the quietness of the cabin was notable. Typically, interior components of a vehicle get noisier as its temperature drops. Not Lucid Air. Its NVH aspect - or Noise, Vibration, and Harshness rating - tested exceptionally well. And for luxury vehicle owners, that's a crucial outcome.\"What else is happening...Taiwan Semiconductor(NYSE:TSM)EPS beats by $0.04, beats on revenue.Shopify(NYSE:SHOP)loses some key execsamid growth push.Bitcoin (BTC-USD)hangs near record high.Oil(CL1:COM)hits highest since mid-Marchon strong demand outlook.Copper(HG1:COM)on path to $15K/ton in 2025thanks to green transition, Goldman says.AstraZenca’s(NASDAQ:AZN)COVID-19 vaccine trumps Ocugen's Covaxinin Indian study.Today's MarketsIn Asia,Japan+0.1%. Hong Kong-0.4%. China-0.5%. India+0.6%.In Europe,at midday, London+0.4%. Paris+0.3%. Frankfurt+0.3%.Futures at 6:20,Dow+0.4%. S&P+0.4%. Nasdaq+0.5%. Crude-0.7%to $62.70. Gold+0.6%at $1747.60. Bitcoin-2%to $62311.Ten-year Treasury Yield-2 bps to1.615%Today's Economic Calendar8:30 Initial Jobless Claims8:30 Philly Fed Business Outlook8:30 Retail Sales8:30 Empire State Mfg Survey9:15 Industrial Production10:00 Business Inventories10:00 NAHB Housing Market Index10:30 EIA Natural Gas Inventory11:30 Fed's Bostic: \"The Atlantic's Progress Report: The State of the Black Community\"2:00 PMFed’s Daly Speech4:00 PMFed’s Mester: \"Economic Inclusion\"4:00 PMTreasury International Capital4:30 PMFed Balance Sheet","news_type":1},"isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}